Phibro Animal Health (NASDAQ:PAHC) Reaches New 1-Year High Following Analyst Upgrade

Phibro Animal Health Corporation (NASDAQ:PAHC)’s share price hit a new 52-week high during trading on Monday after JPMorgan Chase & Co. raised their price target on the stock from $45.00 to $50.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Phibro Animal Health traded as high as $45.13 and last traded at $45.0950, with a volume of 58480 shares changing hands. The stock had previously closed at $43.76.

A number of other brokerages have also recently commented on PAHC. Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 29th. Bank of America upped their price objective on shares of Phibro Animal Health from $19.00 to $27.00 and gave the company an “underperform” rating in a research note on Friday, August 29th. Morgan Stanley set a $34.00 target price on shares of Phibro Animal Health in a research report on Thursday, August 28th. Finally, Weiss Ratings raised shares of Phibro Animal Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $31.40.

Insider Buying and Selling

In other Phibro Animal Health news, CEO Jack Bendheim sold 16,075 shares of Phibro Animal Health stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $40.38, for a total transaction of $649,108.50. Following the sale, the chief executive officer directly owned 23,899 shares of the company’s stock, valued at approximately $965,041.62. The trade was a 40.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last three months, insiders have sold 67,336 shares of company stock valued at $2,734,588. 50.13% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in PAHC. Citigroup Inc. grew its position in Phibro Animal Health by 112.3% during the 3rd quarter. Citigroup Inc. now owns 54,941 shares of the company’s stock valued at $2,223,000 after purchasing an additional 29,066 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its holdings in shares of Phibro Animal Health by 27.7% during the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 14,720 shares of the company’s stock valued at $596,000 after buying an additional 3,190 shares during the last quarter. Jupiter Asset Management Ltd. purchased a new stake in shares of Phibro Animal Health during the third quarter valued at approximately $228,000. JPMorgan Chase & Co. raised its holdings in Phibro Animal Health by 1,730.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock worth $9,634,000 after acquiring an additional 225,110 shares during the last quarter. Finally, Balboa Wealth Partners bought a new position in Phibro Animal Health in the 3rd quarter valued at approximately $216,000. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Trading Up 3.2%

The firm has a market capitalization of $1.83 billion, a PE ratio of 38.28, a P/E/G ratio of 1.24 and a beta of 0.81. The firm has a 50 day simple moving average of $39.71 and a 200 day simple moving average of $31.04. The company has a current ratio of 2.76, a quick ratio of 1.25 and a debt-to-equity ratio of 2.46.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.58 by $0.15. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%.The company had revenue of $363.89 million for the quarter, compared to analysts’ expectations of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. Equities analysts expect that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 17th. Investors of record on Wednesday, November 26th will be given a dividend of $0.12 per share. The ex-dividend date is Wednesday, November 26th. This represents a $0.48 dividend on an annualized basis and a yield of 1.1%. Phibro Animal Health’s dividend payout ratio is 28.92%.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.